Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB

High tumor mutation load (TMB-H, or TMB ≥ 10) has been approved by the U.S. FDA as a biomarker for pembrolizumab treatment of solid tumors, including non‑small cell lung cancer (NSCLC). Patients with cancer who have immunotherapy-resistant gene mutations cannot achieve clinical benefits even in TMB-...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Xia-ye, Wu, Hao, Ye, Bi-cheng, Yi, Qian-wen, Lin, Fang-nan, Wang, Yi-lin, Ren, Chuan-li, Jiang, Yan-fang, Li, Ang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715659/
https://www.ncbi.nlm.nih.gov/pubmed/36456601
http://dx.doi.org/10.1038/s41598-022-25050-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715659/
https://www.ncbi.nlm.nih.gov/pubmed/36456601
http://dx.doi.org/10.1038/s41598-022-25050-3

Ejemplares similares